Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. March 29, 2018. Oliver Schacht.

Executive Summary

Check out what Curetis NV CEO Oliver Schacht had to say about the novel nature of US FDA’s ongoing review of the firm’s multiplex molecular respiratory infection diagnostic.

“FDA … at peak times, had up to 14 reviewers working on this submission, which [it] certainly hinted at as being one of the most complex submissions it has seen.” –Oliver Schacht, CEO, Curetis NV

Click here for a free trial of Medtech Insight


Related Content

Could First-Mover Advantage Make Curetis Ripe For The Picking By Dx Players?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts